Antiviral Therapy 2016; 21:27–35 (doi: 10.3851/IMP2972)
Original article Tenofovir-based antiretroviral therapy in HBV–HIV coinfection: results from the TREAT Asia HIV Observational Database David C Boettiger1*, Stephen Kerr1,2, Rossana Ditangco3, Romanee Chaiwarith4, Patrick CK Li5, Tuti Parwati Merati6, Thuy Thi Thanh Pham7, Sasisopin Kiertiburanakul8, Nagalingeswaran Kumarasamy9, Saphonn Vonthanak10, Christopher KC Lee11, Nguyen Van Kinh12, Sanjay Pujari13, Wing Wai Wong14, Adeeba Kamarulzaman15, Fujie Zhang16, Evy Yunihastuti17, Jun Yong Choi18, Shinichi Oka19, Oon Tek Ng20, Pacharee Kantipong21, Mahiran Mustafa22, Winai Ratanasuwan23, Nicolas Durier24, Matthew Law1, the TREAT Asia HIV Observational Database The Kirby Institute, UNSW Australia, Sydney, Australia HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand 3 Research Institute for Tropical Medicine, Manila, Philippines 4 Research Institute for Health Sciences, Chiang Mai, Thailand 5 Queen Elizabeth Hospital, Hong Kong, China SAR 6 Udayana University, Sanglah Hospital, Denpasar, Indonesia 7 Bach Mai Hospital, Hanoi, Vietnam 8 Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand 9 YRG Centre for AIDS Research and Education, Chennai, India 10 National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia 11 Hospital Sungai Buloh, Sungai Buloh, Malaysia 12 National Hospital of Tropical Diseases, Hanoi, Vietnam 13 Institute of Infectious Diseases, Pune, India 14 Taipei Veterans General Hospital, Taipei, Taiwan 15 University of Malaya Medical Centre, Kuala Lumpur, Malaysia 16 Beijing Ditan Hospital, Capital Medical University, Beijing, China 17 Working Group on AIDS Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia 18 Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea 19 National Center for Global Health and Medicine, Tokyo, Japan 20 Tan Tock Seng Hospital, Singapore 21 Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand 22 Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia 23 Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand 24 TREAT Asia, amfAR – The Foundation for AIDS Research, Bangkok, Thailand 1 2
*Corresponding author e-mail: [email protected]
©2016 International Medical Press 1359-6535 (print) 2040-2058 (online)
AVT-15-OA-3587_Boettiger.indd 27
27
18/02/2016 09:22:45
DC Boettiger et al.
Background: The World Health Organization recommends HBV–HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. Methods: HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observational Database who started first-line antiretroviral therapy were included. Logistic regression adjusted for period of treatment initiation was used to determine factors associated with tenofovir use. Generalized estimating equations were used to evaluate factors associated with alanine transaminase levels and CD4+ T-cell count on treatment. Results: There were 548 eligible patients, of whom 149 (27.2%) started tenofovir. Patients treated in high/highmiddle income countries (odds ratio 4.4 versus low/lowmiddle, 95% CI 2.6, 7.4; P
Original article Tenofovir-based antiretroviral therapy in HBV–HIV coinfection: results from the TREAT Asia HIV Observational Database David C Boettiger1*, Stephen Kerr1,2, Rossana Ditangco3, Romanee Chaiwarith4, Patrick CK Li5, Tuti Parwati Merati6, Thuy Thi Thanh Pham7, Sasisopin Kiertiburanakul8, Nagalingeswaran Kumarasamy9, Saphonn Vonthanak10, Christopher KC Lee11, Nguyen Van Kinh12, Sanjay Pujari13, Wing Wai Wong14, Adeeba Kamarulzaman15, Fujie Zhang16, Evy Yunihastuti17, Jun Yong Choi18, Shinichi Oka19, Oon Tek Ng20, Pacharee Kantipong21, Mahiran Mustafa22, Winai Ratanasuwan23, Nicolas Durier24, Matthew Law1, the TREAT Asia HIV Observational Database The Kirby Institute, UNSW Australia, Sydney, Australia HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand 3 Research Institute for Tropical Medicine, Manila, Philippines 4 Research Institute for Health Sciences, Chiang Mai, Thailand 5 Queen Elizabeth Hospital, Hong Kong, China SAR 6 Udayana University, Sanglah Hospital, Denpasar, Indonesia 7 Bach Mai Hospital, Hanoi, Vietnam 8 Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand 9 YRG Centre for AIDS Research and Education, Chennai, India 10 National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia 11 Hospital Sungai Buloh, Sungai Buloh, Malaysia 12 National Hospital of Tropical Diseases, Hanoi, Vietnam 13 Institute of Infectious Diseases, Pune, India 14 Taipei Veterans General Hospital, Taipei, Taiwan 15 University of Malaya Medical Centre, Kuala Lumpur, Malaysia 16 Beijing Ditan Hospital, Capital Medical University, Beijing, China 17 Working Group on AIDS Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia 18 Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea 19 National Center for Global Health and Medicine, Tokyo, Japan 20 Tan Tock Seng Hospital, Singapore 21 Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand 22 Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia 23 Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand 24 TREAT Asia, amfAR – The Foundation for AIDS Research, Bangkok, Thailand 1 2
*Corresponding author e-mail: [email protected]
©2016 International Medical Press 1359-6535 (print) 2040-2058 (online)
AVT-15-OA-3587_Boettiger.indd 27
27
18/02/2016 09:22:45
DC Boettiger et al.
Background: The World Health Organization recommends HBV–HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. Methods: HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observational Database who started first-line antiretroviral therapy were included. Logistic regression adjusted for period of treatment initiation was used to determine factors associated with tenofovir use. Generalized estimating equations were used to evaluate factors associated with alanine transaminase levels and CD4+ T-cell count on treatment. Results: There were 548 eligible patients, of whom 149 (27.2%) started tenofovir. Patients treated in high/highmiddle income countries (odds ratio 4.4 versus low/lowmiddle, 95% CI 2.6, 7.4; P
